Schedules of Controlled Substances: Diphenidine Scheduling Update
The DEA has updated the diphenidine controlled substance scheduling to reflect its placement in Schedule I. This change addresses the drug's high abuse potential and lack of accepted medical use. Clinicians should stay informed about diphenidine…
Policy Watch: DEA Scheduling Benzodiazepines and Synthetic Drugs — April 01, 2026
This April 01, 2026 policy watch covers DEA scheduling benzodiazepines 2026 updates impacting cannabis clinical practice. The DEA's placement of several benzodiazepine analogs in Schedule I affects co-prescription protocols. These regulatory changes…
Policy Watch: 10 Regulatory Updates — March 20, 2026
The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing its medical utility. This regulatory update impacts prescribing restrictions for healthcare providers. The dea rescheduled marijuana change is a significant development in…
AM Policy Update: DEA Synthetic Opioids Schedule I Placement
The DEA synthetic opioids schedule I placement update on March 17, 2026, highlights key regulatory changes. This update covers multiple synthetic opioids classified under Schedule I. These changes impact controlled substance regulations and cannabis…